This protocol covers male patients aged 18 years or older who present with mild to moderate androgenetic alopecia, corresponding to Hamilton-Norwood grades IIv through V.
Patient scenarioMale sex, age 18 or older, with mild to moderate androgenetic alopecia (Hamilton-Norwood IIv–V). Because androgenetic alopecia is naturally progressive, the clinical aim is both to halt ongoing loss and to stimulate regrowth.
Stopping further hair loss and inducing hair regrowth (increased hair count). Treatment response is evaluated at 6 months.
First-line management centres on scalp-directed topical therapy; the full protocol details agent selection, the criteria for choosing between available options, and follow-up guidance.
Topical Minoxidil 2–5% solution 1 mL or half a cap of 5% foam twice daily is recommended to improve or to prevent progression of AGA in male patients above 18 years with mild to moderate AGA (Hamilton-Norwood IIv-V).
We suggest using 5% solution or half a cap of 5% foam for greater efficacy.
Oral Finasteride 1 mg/day is recommended to improve or to prevent progression of AGA in male patients above 18 years with mild to moderate AGA (Hamilton-Norwood IIv-V).
As AGA is a naturally progressive disease, therapy can have two required outcomes, namely stop of hair loss and induction of hair regrowth.
The response to treatment should be assessed at 6 months.
View source ↗